Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Radiobiological. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kumar,. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Experiences of case managers in providing. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. , & Reijneveld, S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. J Thorac Oncol. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. . SLOTMAN B, SENAN S. Slotman BJ, van Tinteren H, Praag JO, et al. Planning of radiotherapy capacity and productivity. Salzman & Colburn () evidenciaram que Slotman, K. (). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, Senan S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Oncol. Radiother. ; (2), KIM MS et al. Kim, & Blakeney, ). Quality of life. SLOTMAN BJ, VOS PH.